Chardan Capital Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock

Alto Neuroscience (NYSE:ANRO) had its target price upped by Chardan Capital from $15.00 to $30.00 in a report released on Monday, MarketBeat reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price objective points to a potential upside of 99.40% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. BTIG Research initiated coverage on Alto Neuroscience in a research note on Monday, November 17th. They issued a “buy” rating and a $27.00 target price on the stock. Robert W. Baird upped their price target on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Finally, HC Wainwright increased their price objective on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.33.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $15.05 on Monday. The company has a 50-day simple moving average of $15.00 and a two-hundred day simple moving average of $8.02. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $20.91. The firm has a market cap of $467.45 million, a price-to-earnings ratio of -6.57 and a beta of 2.78.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. On average, equities analysts forecast that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

A number of institutional investors have recently bought and sold shares of ANRO. Armistice Capital LLC raised its holdings in shares of Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the last quarter. Vanguard Group Inc. increased its position in Alto Neuroscience by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after purchasing an additional 20,702 shares in the last quarter. Marshall Wace LLP increased its position in Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares in the last quarter. Millennium Management LLC raised its stake in Alto Neuroscience by 4.3% in the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock valued at $1,269,000 after purchasing an additional 12,896 shares during the last quarter. Finally, Peapod Lane Capital LLC lifted its holdings in Alto Neuroscience by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after purchasing an additional 3,106 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.